The therapeutic applications of Барбовал are focused on providing supportive symptomatic relief in situations where emotional stress and nervous system over-excitation are associated with both psychological distress and symptoms related to physical discomfort.

The active components in this medication are used in clinical contexts to assist with managing discomfort related to both nervous activity and smooth muscle spasm. It is generally applied across three therapeutic domains and supports the maintenance of functional stability when symptoms become more noticeable, particularly in mild neurotic conditions, functional cardiovascular disorders, and sleep initiation difficulties.

This medicine is commonly used for instances of emotional agitation or hyper-irritability associated with functional nervous system disorders. The core benefit provided plays a role in managing emotional distress, which may assist with managing feelings of apprehension and supports patients during episodes of heightened discomfort related to daily stress and overload.

“The supportive benefit is aimed at easing both the emotional manifestations and the related physical symptoms associated with nervous tension.”

The preparation is relevant in clinical settings marked by heightened physical tension and spasms of the smooth muscle. It is applied in addressing symptom clusters such as Functional Cardialgia, episodes of Sinus Tachycardia triggered by anxiety, and insomnia rooted in nervous over-excitation. This supportive therapeutic benefit contributes to relieving the overall symptom load and supports general well-being during symptomatic phases.

Quick Fact: Symptomatic Support for Nervous Tension The combination of sedative and antispasmodic properties is commonly used when symptoms of nervous strain affect both psychological state and physical comfort, and is considered relevant in the context of mild functional disorders and stress-related sleep disturbances.

Regulatory References

1. NIH MedlinePlus overview of Phenobarbital combination products

Population Eligibility and Restrictions

Eligibility for Барбовал is strictly defined by regulatory documents, focusing on contraindications and conditional use requirements primarily stemming from its Phenobarbital component. Use is generally restricted to the adult population (18 years and older) who do not possess specific medical exclusions.

Absolute Non-Eligibility (Contraindicated)

Age-Related Rules and Conditional Use

The official labeling also dictates caution for patients with severe respiratory depression, uncontrolled pain, and specific cardiovascular issues like severe cardiac failure. This strict regulatory profile ensures the medicine is only used within officially defined safety parameters.

Interactions with other medicines and products

The documented interaction profile for Барбовал is primarily defined by the actions of its Phenobarbital component, which is officially classified as a potent inducer of hepatic cytochrome P450 enzymes (e.g., CYP3A4). This pharmacokinetic interaction accelerates the metabolism of various co-administered medicines, leading to significantly decreased plasma concentrations and reduced therapeutic effect.

Affected drug classes include oral hormonal contraceptives, oral anticoagulants (like Warfarin), and systemic corticosteroids, requiring specific constraints. For instance, the reduced exposure of hormonal contraceptives may necessitate the use of alternative barrier methods. Specific combinations are formally designated as contraindicated by regulatory authorities due to high risk, such as co-administration with calcium/magnesium/potassium/sodium oxybates and certain HIV antivirals.

A separate pharmacodynamic interaction occurs with other Central Nervous System (CNS) depressants, resulting in additive effects. Co-administration with alcohol (ethanol), opioids, and other sedatives may lead to intensified sedation and risk of respiratory depression. The regulatory profile also notes that the co-administration of medicines like Valproic Acid can inhibit Phenobarbital's metabolism, leading to an official increase in Phenobarbital’s systemic exposure. Furthermore, the product is associated with potential reductions in the body’s levels of vitamins such as Folate and Vitamin D.

The primary mechanism of action of the barbiturate component involves the GABAA receptor complex in the central nervous system. The compound acts as a positive allosteric modulator, binding to a distinct site on the receptor, which enhances the inhibitory effects of the endogenous neurotransmitter gamma-aminobutyric acid (GABA). This interaction prolongs the duration of the opening of the neuronal chloride ion channel. The resulting increased influx of negatively charged chloride ions into the post-synaptic neuron causes hyperpolarization of the cell membrane, which subsequently raises the threshold for action potential generation and reduces overall neuronal excitability. Furthermore, this component acts as an antagonist at certain excitatory neurotransmitter receptors, specifically inhibiting the actions mediated by glutamate. This dual modulation—potentiating inhibitory signals while antagonizing excitatory ones—results in a generalized decrease in neuronal firing rates and suppression of abnormal electrical propagation within the central nervous system.

Official Administration Guidelines

These guidelines detail the standardized administration of Барбовал as prescribed in its regulatory labeling. Adherence to these instructions is required for the correct use of the medicine, and they do not constitute medical advice or include information on indications or safety.

Administration Scope

The medicine is supplied as a liquid oral dosage form (drops) and is administered by the oral route. The dose is precisely defined by the number of drops taken per administration.

Procedural Structure

The official instructions establish a fixed procedural sequence for use. The user must first measure the specific number of drops (10–15) and combine them with a small amount of water. This mixture is then administered orally at the specified time relative to meals. The required administration is repeated according to the daily frequency, strictly until the defined course duration is completed. This protocol defines the authorized administration method and cycle. The regimen is typically applied to adults.

Research Evidence / Overview of Studies for Барбовал

Evidence for Supportive Relief in Mild Nervous Tension and Agitation

The research on the use of Барбовал was studied in contexts exploring symptoms of mild nervousness, hyper-irritability, and emotional agitation, which are conditions characterized by fluctuating or episodic manifestations. The existing evidence primarily comes from pharmacological studies related to combined sedative agents, alongside regulatory summaries and clinical overviews of similar combination products.

Studies examined outcomes related to systemic or functional imbalance, such as patient-reported measures of agitation. However, the certainty remains low for this application, as the available information largely relies on the known pharmacological properties of the active ingredients. Follow-up durations were limited, and there is limited information for long-term outcomes.

Evidence for Symptomatic Support in Functional Physical Tension and Spasm

The preparation was evaluated in research exploring its dual action, which includes the components studied for outcomes related to physical discomfort and nervous tension. Studies monitored outcomes related to systemic or functional imbalance, such as smooth muscle spasms and physical tension. This application was studied for conditions involving periods of heightened symptoms, such as functional cardiovascular issues like Functional Cardialgia.

Evidence is primarily derived from pharmacological studies exploring the sedative and antispasmodic properties of the components. Data show patterns related to outcomes reflecting daily functioning or activity level in contexts associated with nervous system over-excitation.

Uncertainties and Research Gaps

The overall evidence quality varies across studies and across the different indications for Барбовал. Certainty remains low for many applications, as its foundation appears to rely on pharmacological principles rather than contemporary large-scale, comparative clinical trials. Comparative evidence is lacking for this specific combination product. There is limited information for long-term outcomes, and data for certain groups remain insufficient, particularly for individuals outside the general adult populations studied.

Key Studies & References Phenobarbital Combinations (Oral Route) Overview - MedlinePlus Drug Information

Common questions about Барбовал (FAQ)

Q: Does Барбовал cause drowsiness or make it difficult to drive?

A: The primary component in this medicine is associated with drowsiness (somnolence), which is documented as a common side effect in official product information. Due to this potential effect on the central nervous system, official regulatory restrictions indicate that the medicine may impair the ability to drive or operate complex machinery.

Q: Can I take Барбовал if I drink alcohol?

A: Co-administration of this medicine with alcohol (ethanol) is specifically documented in the regulatory profile as increasing the risk of intensified central nervous system (CNS) depressant effects. The potential for intensified sedation is a key safety concern described in regulatory warnings regarding this combination.

Q: What are the most common side effects reported with Барбовал?

A: According to official safety data, the most commonly reported adverse reaction is drowsiness (somnolence). Other potential nervous system effects that have been reported include dizziness, agitation, and confusion.

Q: Can people with liver issues use Барбовал?

A: Official regulatory documents state that the use of this medicine is contraindicated (absolutely prohibited) in individuals with severe hepatic (liver) insufficiency. Patients with any degree of liver impairment, other than severe, should only use the medicine under medical guidance, as the medication is processed by the liver.

Q: Is it possible to become dependent on Барбовал?

A: There is a formally documented risk of both physical and psychological drug dependence associated with the primary active component. Official guidelines emphasize that the risk of dependence is associated with prolonged, uninterrupted use.

Q: Is it normal to feel a mild dizziness after taking Барбовал?

A: Dizziness is listed in the official adverse reaction data as a potential nervous system effect. It is a recognized possibility, alongside feelings of lethargy or residual sedation from the medicine.

Q: How long after taking Барбовал is it safe to operate machinery?

A: The action of the main component typically lasts for 5 to 6 hours or longer. Official instructions indicate that operating machinery is not recommended until the effects have fully worn off, as the medicine may impair mental abilities.

Q: Can a person stop using Барбовал suddenly?

A: Abrupt cessation (stopping suddenly) after prolonged use is formally advised against. Abrupt cessation may be associated with the occurrence of withdrawal symptoms, which can include signs such as anxiety, muscle twitching, and insomnia.

Q: How quickly can I expect to notice any effects after taking Барбовал?

A: Based on the pharmacological properties of the main component, the onset of action typically occurs within 30 minutes of administration.

Q: Is it safe to use Барбовал every day for a long period?

A: Long-term daily use is associated with specific risks beyond the defined course duration. Official warnings state that the risks include the potential for drug dependence and changes to bone mineral density and vitamin levels.

Q: Can Барбовал affect my blood pressure readings?

A: The adverse reaction profile of the medicine includes the possibility of changes in cardiovascular function, specifically reporting hypotension (low blood pressure) and circulatory collapse. These effects can, therefore, influence blood pressure readings.

Q: Can I take Барбовал on an empty stomach?

A: The official administration guidelines for the medicine advise taking the drops before meals, typically 20 to 30 minutes prior to eating. This timing suggests administration on an empty or near-empty stomach.

Q: How long does the effect of Барбовал usually last?

A: The sedative effect of the medicine’s primary component typically has a duration of action ranging from 5 to 6 hours per dose.

Q: Does taking Барбовал affect the results of blood tests?

A: The medicine’s use is associated with a potential reduction in the body's levels of vitamins such as Folate and Vitamin D. Additionally, it can lead to conditions like Megaloblastic Anemia, which would be reflected in blood test results.

Q: What is the active substance in Барбовал that helps with anxiety?

A: The primary component, Phenobarbital, is the substance responsible for the calming effects. It works as a central nervous system (CNS) depressant by enhancing the inhibitory signals in the brain, which in turn reduces overall neuronal excitability and helps relieve emotional distress.

Q: How is Барбовал different from natural calming remedies?

A: Барбовал is classified as a polycomponent medicine that is a synthetic compound. This core identity makes it distinct from single-ingredient herbal or purely natural calming remedies.

Q: Does the use of Барбовал have any influence on sleep quality?

A: The common adverse effect of the main component is somnolence (drowsiness) and the potential for a residual sedation or 'hangover' effect the next day. These effects are an influence on the body’s sleep-wake cycle.

Q: Can I take pain relievers like paracetamol with Барбовал?

A: The official product information notes that co-administration of the main component with Acetaminophen (Paracetamol) can potentially alter the effects of the pain reliever. The combination is noted for potentially raising concerns regarding liver toxicity.

Q: Why do people sometimes use Барбовал for stomach spasms?

A: The medicine is pharmacologically classified as a combined sedative and antispasmodic agent. The antispasmodic property is intended to help ease associated physical tension and spasms.

Q: Is there a risk of overdose with Барбовал?

A: Yes, the official labeling includes information on overdosage (acute intoxication) with the medicine's components. Overdose is a serious medical emergency that can lead to symptoms such as slowed breathing, decreased consciousness, and circulatory collapse.

Q: Can using Барбовал cause or worsen depression?

A: The adverse reaction profile includes the possibility of new or increased feelings of anxiety or depression. Furthermore, official warnings note reports of suicidal thoughts or actions associated with the main component.

Q: Is it okay to store Барбовал in the bathroom cabinet?

A: Official storage instructions specify that the medicine must be kept at a temperature not higher than 25 C and be protected from light and moisture. The user should review the storage requirements against the environmental conditions of the storage location, such as a bathroom cabinet.

Q: Can I use Барбовал at the same time as cold and flu medications?

A: The interaction profile contains warnings about co-administration with other CNS depressants, which can include certain ingredients found in cold and flu medicines (like antihistamines). Combining these may result in additional CNS depressant effects and intensified sedation.

Q: What components in Барбовал are considered herbal?

A: The medicine is officially classified as a synthetic compound. The two primary active ingredients, Phenobarbital and Ethylbromisovalerinate, are not described as herbal in the official regulatory profile.

Q: Does Барбовал contain any ingredients that cause allergic reactions?

A: The official safety documentation includes the possibility of severe hypersensitivity reactions (allergic reactions). The medicine is formally contraindicated for individuals with known hypersensitivity to barbiturates or any of its components.

Q: Do official documents mention any effects of Барбовал on focus or concentration?

A: Yes, official warnings state that the medicine may impair mental abilities required for potentially hazardous tasks. Side effects such as confusion, lethargy, and thinking abnormality are reported in the adverse reaction data.

Q: Can people with kidney problems use Барбовал?

A: The use of the medicine is contraindicated (absolutely prohibited) in cases of severe renal (kidney) insufficiency. Caution and close monitoring are required for patients with less severe kidney impairment.

Q: How does the listed 'menthol isovalerate' in Барбовал contribute to its effect?

A: Menthyl isovalerate is a component associated with a mild calming or anxiolytic effect in relevant pharmacological literature. It acts as an additive in the liquid formulation to contribute to the medicine's overall sedative properties.

Q: Are there any long-term health risks associated with Барбовал use?

A: Chronic use of the medicine is associated with long-term risks. Official warnings state that the risks include the potential for drug dependence, decreased bone mineral density, and deficiencies of specific vitamins.

Q: Is Барбовал known to interact with birth control pills?

A: Yes, the medicine is known to interact with oral hormonal contraceptives (birth control pills). This interaction may lead to decreased plasma concentrations and a reduced therapeutic effect of the contraceptive, requiring cautionary measures.

Q: Does Барбовал cause rebound anxiety when stopped?

A: Regulatory documentation on the cessation of the main component notes that withdrawal symptoms can occur after prolonged use. These symptoms can include signs such as increased anxiety, muscle twitching, and insomnia.

Q: Is there any evidence about its effect on chronic stress?

A: Official evidence primarily relates to symptoms of mild nervousness, hyper-irritability, and emotional agitation. Official product information notes that the overall certainty of evidence remains low for applications outside of these defined areas.

Q: Are there different strengths or formulations of Барбовал?

A: The medicine is primarily supplied as a single liquid solution (drops) for oral administration. The official guidelines define a single administration range of 10 to 15 drops.

The official regulatory guidelines for storing and disposing of Барбовал are focused on protecting the liquid formulation from degradation and ensuring safety.

Official Storage Requirements

Disposal Instructions

Disposal of unused or expired Барбовал and its container must be completed in accordance with all local, regional, and national regulations. As a pharmaceutical product, releases to the environment, particularly into wastewater systems, must be avoided. The standard method for disposal often involves utilizing a local drug take-back program.